Hematology Analyzers and Reagents Market Size, Share and Global Trend By Product Type (Instruments, Reagents), By End User (Diagnostic laboratories, Hospitals & Clinics, Research institutes, Others), and Regional Forecast, 2024-2032

In February 2019, ERBA Diagnostics launched the company’s newly developed hematology analyzers in MEDLAB 2019. Hematology analyzer and reagents are used for blood tests that provide qualitative and quantitative data regarding white blood count, red blood count, and coagulation test.

The recent product launches by major players are projected to fuel the global hematology analyzer and reagents market growth during the forecast period. Additionally, the increasing awareness regarding chronic diseases and the importance of maintaining good health among patient population is estimated to boost the global hematology analyzers and reagent market potential.

The global hematology analyzers and reagents market growth is being driven by many factors such as recent technological advancement in the field and the current product launches. For instance, in May 2018, Beckman Coulter announced the launch of DxH 900 hematology analyzer and is available in Europe, United States, New Zealand, and Australia.

Combined with this, the rise in the prevalence of diseases like sickle cell anemia, blood cell cancer, HIV, among others, are anticipated to drive the global hematology analyzers and reagents market positively. According to the American Society of Hematology, 3 million people in America suffer from anemia.

Slow adoption of automated hematology analyzers in emerging countries and high cost of equipment are considered to restrain the growth of global hematology analyzers and reagents market.

Key Players Covered

Key players operating in the global hematology analyzers and reagents market are ERBA Diagnostics, Siemens AG, Beckman Coulter, Sysmex Corporation, Bio-Rad Laboratories, Abbott Laboratories, Ortho Clinical Diagnostics Hoffmann-La Roche Ltd and other players.

SEGMENTATION 

At present, among product types, the instruments are likely to hold the major share of the global hematology analyzers and reagents market due to the high cost associated with the analyzers.

Key Insights

• New product launches


• Overview of regulatory scenario for key countries


• Key mergers and acquisitions


• Prevalence of major hematological disorder – key countries

Regional Analysis

The global hematology analyzers and reagents market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is estimated to dominate the global hematology analyzer and reagents industry owing to the robust presence of major players and increasing investment to develop novel and higher accurate result generating medical devices. Europe is projected to follow the lead in the global hematology analyzers and reagents market due to the increase in the number of diagnostic clinics and raising awareness of hematological disorders. The global hematology analyzers and reagent market opportunity is projected to be the highest in the untapped markets of Asia Pacific, Latin America and the Middle East and Africa owing to the increasing prevalence of hematological disorders among the patient population.

Hematology Analyzers and Reagents Industry Developments

• In November 2018, PixCell Medical Technologies Ltd. received 510(k) approval from the U.S Food and Drug Administration approval for the company’s HemoScreen hematology analyser for point-of-care use.


• In March 2018, U.S FDA cleared Roche's cobas m 511 hematology analyzer.


• In May 2019, Beckman Coulter was issued a Class 1 device recall for DxH 800, DxH 600, and DxH 900 hematology analyzers from the U.S FDA owing to inaccurate results.